Brain Cancer Clinical Trials

Showing 901-920 of 1,466 trials

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

NCT00871923

The goal of this clinical research study is to learn whether Tarceva (erlotinib hydrochloride), when given in addition to whole brain radiation therapy, is better to treat brain metastases in patients with Non-Small Cell Lung Cancer (NSCLC).

Non-small Cell Lung CancerBrain Cancer

M.D. Anderson Cancer Center44 participantsStarted Mar 2009

Tucson, Arizona, United States • Houston, Texas, United States

COMPLETED

National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry

NCT04351035

Tumours of central nervous system (CNS) is the most common type of solid tumour in childhood. In China, there is limited epidemiology information. Released data from Chinese CDC did not include types of CNS tumours and geographic contribution. As the Children's Neuro-Oncology Group (CNOG) was established in China in May 2017, it makes studies from multiple centers in children's brain tumors become practical. This retrospective cross-sectional study was aligned on CNOG annual meeting in 2018 and research group was named as CNOG-MC001 (MC, multicenter) collaborative group.

Tumors, Central Nervous SystemPediatric Brain TumorMalignant Brain Tumor+1 more

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine4,303 participantsStarted Oct 2018

Hefei, Anhui, China • Beijing, Beijing Municipality, China • Chongqing, Chongqing Municipality, China +35 more locations

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry

Related Searches

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme

Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme

fMRI Study of Functional Reorganization in Glioma Patients

Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform

FMISO PET Study of Glioblastoma

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas

Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification Algorithms

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)

Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme.